New Study Reveals FDA Relied on Cherrypicked Data to Approve Dangerous Mail-Order Abortion Drugs

A new peer-reviewed article highlights major flaws in the data used by the U.S. Food and Drug Administration (FDA) to remove medical safeguards and in-person administering of abortion drugs. These flaws illustrate the ongoing problem of lack of quality abortion reporting data in the U.S. as well as in the United Kingdom.

In April 2021, the FDA removed mifepristone’s in-person requirements, temporarily allowing remote access to abortion drugs during the COVID-19 pandemic, later making these changes permanent in December 2021.